Pharma DECODED
Previous edition: 09 May 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
FDA fast track status granted to iECURE neonatal OTC deficiency treatment
ECUR-506 is being evaluated in the first-in-human Phase I/II OTC-HOPE study.
The US Food and Drug Administration (FDA) has granted fast track designation for iECURE’s gene editing therapy, ECUR-506, for the treatment of neonatal onset ornithine transcarbamylase (OTC) deficiency.
ECUR-506 is an in vivo gene insertion programme.
The status will accelerate the development and review of treatments for serious conditions with unmet medical needs.
The company can now hold frequent interactions with the FDA to discuss the development plan and appropriate data collection for potential approval.
The therapeutic benefits of ECUR-506 have been recognised previously, with the FDA awarding it rare paediatric disease and orphan drug designations.
The European Commission also granted orphan designation for the treatment of OTC deficiency.
ECUR-506 is being evaluated in the Phase I/II OTC-HOPE study, a first-in-human trial targeting newborn males with genetically confirmed neonatal onset OTC deficiency.
The study is enrolling participants at the Great Ormond Street Hospital for Children in London, UK with additional sites in the US and Australia set to commence enrolment later in 2024.
The OTC-HOPE study is focused on enrolling newborn males aged up to seven months diagnosed with severe neonatal onset OTC deficiency.
Its primary goal is to evaluate the safety and tolerability of a single intravenous dose of ECUR-506.
Secondary objectives include evaluating the pharmacokinetics and efficacy of the therapy.
Exploratory endpoints will investigate disease-specific biological markers, developmental milestones and the impact on the patient's quality of life.
iECURE CEO Joe Truitt stated: “Receipt of fast track designation from the FDA is a validation of the severe unmet need for patients with neonatal onset OTC deficiency and a testament to the preclinical data generated to date for ECUR-506.
“The benefits of fast track designation may accelerate our ability to get ECUR-506 into physicians’ hands, which is incredibly important when every second counts for these babies.”
Latest news
ESCMID 2024: Emerging bacterial infections in neonates and children
Coinfections can complicate disease management and hence continued surveillance and targeted intervention strategies are needed.
Sobi's Aspaveli obtains indication extension approval in Europe
The approval for Aspaveli's extended indication is based on data from the APL2-308 (PRINCE) study.
Biotechs must prioritise ethics to deter GenAI “bad actors”
At the London Biotechnology Show, Microsoft’s senior director of life sciences discussed the ethical use of GenAI.
Zenas raises $200m to advance autoimmune antibody therapy
Zenas signed a licensing deal for Asia-Pacific territories for the bispecific antibody therapy, obexelimab, with Bristol Myers Squibb in September 2023.
Regenex Bio eyes FDA meeting to confirm pivotal DMD trial
Regenex Bio will sit down with the FDA in Q3 2024 to finalise the Phase III trial design.
Acepodia reports preliminary results from ACE1831 Phase I trial
The preliminary data indicates potential benefits for non-Hodgkin's lymphoma patients.
Teva and Medincell report positive data for TEV-‘749 in schizophrenia trial
TEV-‘749 has met primary endpoint in Phase III trial, showing significant symptom reduction in schizophrenia patients.
15th Annual Outsourcing in Clinical Trials East Coast 2024
The upcoming Outsourcing in Clinical Trials Europe 2024 conference will explore advancements in the clinical trial industry.
In our previous edition
Pharma Decoded
AstraZeneca to withdraw Covid-19 vaccine globally
08 May 2024
Pharma Decoded
BioNTech reports net loss of €315.1m in Q1 2024
07 May 2024
Pharma Decoded
Amgen reports a 22% increase in Q1 2024 net revenues
06 May 2024
Newsletters in other sectors
Aerospace, Defence & Security
Medical Devices
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer